Kim, Hyoung http://orcid.org/0000-0002-9975-8545
Xu, Haineng http://orcid.org/0000-0001-7195-4897
George, Erin
Hallberg, Dorothy
Kumar, Sushil
Jagannathan, Veena
Medvedev, Sergey
Kinose, Yasuto
Devins, Kyle
Verma, Priyanka
Ly, Kevin
Wang, Yifan
Greenberg, Roger A.
Schwartz, Lauren
Johnson, Neil
Scharpf, Robert B.
Mills, Gordon B. http://orcid.org/0000-0002-0144-9614
Zhang, Rugang http://orcid.org/0000-0002-7255-2360
Velculescu, Victor E. http://orcid.org/0000-0003-1195-438X
Brown, Eric J.
Simpkins, Fiona http://orcid.org/0000-0002-0840-2368
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5R37CA215436-02, 1P50CA228991, 5R01CA189743, CA006973, CA121113, CA217685)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Defense (OC150336)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Rivkin Center for Ovarian Cancer
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Ovarian Cancer Research Fund
Kaleidoscope of Hope Ovarian Cancer Foundation
Article History
Received: 16 February 2020
Accepted: 4 June 2020
First Online: 24 July 2020
Competing interests
: The following authors declare competing interests. F.S. serves on the scientific advisory board for AstraZeneca (unpaid). E.J.B. serves on the scientific advisory board of Atrin Pharmaceuticals and has been an advisor for Sierra Oncology. RAG has consulted for Agios Pharmaceuticals and MoMa Therapeutics. V.E.V. is a founder of Personal Genome Diagnostics, a member of its Scientific Advisory Board and Board of Directors, and owns Personal Genome Diagnostics stock, which are subject to certain restrictions under university policy. V.E.V. is an advisor to Takeda Pharmaceuticals. Within the last 5 years, V.E.V. has been an advisor to Daiichi Sankyo, Janssen Diagnostics, and Ignyta. R.B.S. is a founder of and holds equity in Delfi Diagnostics. He also serves as the Head of Data Sciences at Delfi Diagnostics. The terms for these arrangements for V.E.V. and R.B.S. has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. G.B.M. receives support or acts as a consultant for AstraZeneca, ImmunoMET, Ionis, Nanostring, PDX Pharmaceuticals, Signalchem Lifesciences, Symphogen, and Tarveda and has transferred technology to Myriad and Nanostring. The remaining authors declare no competing interests.